KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Non-Current Debt: 2012-2019

Historic Non-Current Debt for Nektar Therapeutics (NKTR) over the last 8 years, with Dec 2019 value amounting to $250.0 million.

  • Nektar Therapeutics' Non-Current Debt rose 3.00% to $254.8 million in Q1 2020 from the same period last year, while for Mar 2020 it was $254.8 million, marking a year-over-year increase of 3.00%. This contributed to the annual value of $250.0 million for FY2019, which is 1.24% up from last year.
  • Nektar Therapeutics' Non-Current Debt amounted to $250.0 million in FY2019, which was up 1.24% from $246.9 million recorded in FY2018.
  • In the past 5 years, Nektar Therapeutics' Non-Current Debt registered a high of $250.0 million during FY2019, and its lowest value of $241.7 million during FY2015.
  • Moreover, its 3-year median value for Non-Current Debt was $246.9 million (2018), whereas its average is $247.4 million.
  • Data for Nektar Therapeutics' Non-Current Debt shows a peak YoY skyrocketed of 93.36% (in 2015) over the last 5 years.
  • Yearly analysis of 5 years shows Nektar Therapeutics' Non-Current Debt stood at $241.7 million in 2015, then rose by 0.73% to $243.5 million in 2016, then climbed by 0.72% to $245.2 million in 2017, then rose by 0.71% to $246.9 million in 2018, then increased by 1.24% to $250.0 million in 2019.